9125905

2 known cases. View patent page →

Cases
2
Active
0
2 closed
Filed
2015
Top venue
D Del Judge Gregory M Sleet
1 case

Helsinn Healthcare S.A. et al. v. Fresenius Kabi USA, LLC

voluntarily dismissed without prejudice
Docket:
1:15-cv-00918
Filed:
2015-10-13
Terminated:
2015-12-01
Patents:91259057947724851898185982189066980
π Helsinn Healthcare S.A.π Roche Palo Alto LLCΔ Fresenius Kabi USA, LLC

Helsinn and Roche asserted U.S. Patents 7,947,724; 8,518,981; 8,598,218; 9,066,980; and 9,125,905 against Fresenius Kabi in D. Del. based on Fresenius's Notice Letter regarding NDA No. 208109 for palonosetron HCl IV. Helsinn voluntarily dismissed the action without prejudice on 2015-12-01, and it was essentially refiled in New Jersey.

Helsinn Healthcare S.A. et al. v. Qilu Pharmaceutical Co., Ltd. et al.

closed/dismissed
Docket:
15-cv-08132
Filed:
2015-11-17
Patents:9125905794772490669809173942
π Helsinn Healthcare S.A.π Roche Palo Alto LLCΔ Qilu Pharmaceutical Co., Ltd.Δ Qilu Pharma, Inc.

Helsinn and Roche filed a patent-infringement action against Qilu in D.N.J. after Qilu's Paragraph IV letter regarding the '905 patent. The case was closed/dismissed, but the narrative notes uncertainty whether the '905 patent itself was pleaded; FDA's tentative-approval letter described the Qilu litigation as asserting the '724, '094, '980, and '942 patents instead.